β¨ Health Notices
12 SEPTEMBER
NEW ZEALAND GAZETTE
3627
This designation is subject to the following conditions:
-
The auditing agency must ensure that where it audits
the provision of health care services for people with
mental illnesses, a past or present consumer of mental
health services must fully participate in all aspects
of the audit. -
The auditing agency must inform the Ministry of
Health immediately by way of written notice if
there is any change to their accreditation status with
JAS-ANZ.
This designation will expire three years after the date of this
notification in the New Zealand Gazette.
Dated at Wellington this 6th day of September 2002.
KAREN O. POUTASI, Director-General of Health.
go6148
Medicines Act 1981
Consent to the Distribution of a New Related Product
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of
the new related product set out in the Schedule hereto:
Schedule
Product:
Macleans Protect Coolmint
Active Ingredient:
Sodium fluoride 0.221%w/w
Dosage Form:
Toothpaste
New Zealand Sponsor:
SmithKline Beecham (NZ) Limited
Manufacturer:
GlaxoSmithKline Australia Pty Limited, Ermington, New South Wales, Australia
Dated this 9th day of September 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go6214
Consent to the Distribution of a Changed Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of
the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set
out in the Schedule hereto:
Schedule
Product:
Zorac
Active Ingredient:
Tazarotene 0.5mg/g
Dosage Form:
Topical gel
New Zealand Sponsor:
Allergan New Zealand Limited
Manufacturer:
Allergan Inc., Waco, Texas, United States of America
Product:
Zorac
Active Ingredient:
Tazarotene 1mg/g
Dosage Form:
Topical gel
New Zealand Sponsor:
Allergan New Zealand Limited
Manufacturer:
Allergan Inc., Waco, Texas, United States of America
Dated this 9th day of September 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go6215
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or
use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product:
AHF (High Purity) Dried Factor VIII Fraction
Active Ingredient:
Factor VIII, human 250IU
Dosage Form:
Powder for injection
New Zealand Sponsor:
CSL (New Zealand) Limited
Manufacturer:
CSL Limited, Bioplasma Division, Broadmeadows, Victoria, Australia
Note: This consent is valid for two years from 25 February 2003.
Dated this 9th day of September 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go6216
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2002, No 135
Gazette.govt.nz —
NZ Gazette 2002, No 135
β¨ LLM interpretation of page content
π₯
Designation of Auditing Agency for Health Care Services
(continued from previous page)
π₯ Health & Social Welfare6 September 2002
Health and Disability Services, Auditing Agency, Verification New Zealand Limited
- KAREN O. POUTASI, Director-General of Health
π₯ Consent to Distribution of New Related Product
π₯ Health & Social Welfare9 September 2002
Medicines, Toothpaste, Macleans Protect Coolmint, Sodium fluoride
- G. R. BOYD, Chief Advisor, Safety and Regulation
π₯ Consent to Distribution of Changed Medicine
π₯ Health & Social Welfare9 September 2002
Medicines, Zorac, Tazarotene, Topical gel
- G. R. BOYD, Chief Advisor, Safety and Regulation
π₯ Renewal of Provisional Consent to Distribution of New Medicine
π₯ Health & Social Welfare9 September 2002
Medicines, AHF (High Purity) Dried Factor VIII Fraction, Factor VIII, Powder for injection
- G. R. BOYD, Chief Advisor, Safety and Regulation